Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

SCRI Development Innovations

Status and phase

Completed

Phase 2

Conditions

Lung Cancer

Treatments

Drug: Carboplatin

Drug: Imatinib

Drug: Irinotecan

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00193349

CSTI571BUS66

SCRI LUN 59

CPTAIV-0020-403

Details and patient eligibility

About

This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.

Full description

Upon determination of eligibility, all patients will be receive:

Irinotecan + Carboplatin + Imatinib

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria:

Small cell lung cancer with extensive stage disease confirmed by biopsy
Measurable or evaluable disease
Ability to perform activities of daily living with minimal assistance
Adequate bone marrow, liver and kidney
No active brain metastasis.
No previous chemotherapy or radiation therapy
Give written informed consent.

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

Limited stage disease (includes IA, IB, IIA, IIB, and IIIA)
Active brain metastasis
Age < 18 years old
History of a prior malignancy within three years
Women pregnant or lactating.

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.